Executive Summary / Key Takeaways
-
Schrödinger has executed a decisive strategic pivot, ending independent clinical development while preserving high-value partnerships, which will save approximately $70 million annually and accelerate the path to positive adjusted EBITDA by 2028 without sacrificing the upside from proprietary programs.
-
The company's physics-based computational platform represents a durable moat in the AI age, providing the essential "ground truth" data that AI models require for drug discovery, a capability that competitors cannot replicate through machine learning alone.
-
A deliberate transition to hosted software contracts will suppress near-term revenue recognition but create a more predictable, higher-quality revenue stream, with management targeting 75% hosted revenue by 2028.
-
Despite 23% revenue growth and a strong balance sheet with $402 million in cash, the stock trades at 3.2x sales, a valuation that suggests the market has not yet recognized the magnitude of the operational inflection.
-
The investment thesis hinges on execution of the hosted transition and successful partnering of Phase 1 assets, while key risks include customer concentration in pharma and persistent biotech sector weakness that could delay scale-up opportunities.
Setting the Scene: The Physics-Based Discovery Platform
Schrödinger, founded in 1990 and headquartered in New York, operates a computational platform that integrates physics-based simulations with AI to accelerate molecular discovery across life sciences and materials science. The company generates revenue through two distinct segments: a software licensing business that sells access to its platform, and a drug discovery segment that leverages the same technology to advance proprietary and collaborative programs toward milestones and royalties.
The software segment represents the stable, recurring foundation of the business, generating $199.5 million in 2025 revenue with 74% gross margins. The drug discovery segment contributed $56.4 million in 2025, more than doubling from 2024, but remains inherently volatile due to milestone timing and collaborator decisions. This dual-engine model creates a unique value proposition: the software business provides predictable cash flow while the drug discovery segment offers asymmetric upside through equity stakes and milestone payments that have already generated approximately $600 million in cash since 2020.
Industry structure favors Schrödinger's approach. The biosimulation market is growing at 16-17% annually, driven by pharmaceutical companies seeking to reduce R&D costs and accelerate timelines. Traditional drug discovery suffers from high failure rates and escalating costs, creating demand for computational approaches that can predict molecular behavior before expensive laboratory work. Schrödinger sits at the intersection of this trend, with a platform that becomes more valuable as AI adoption increases computational throughput.
Technology, Products, and Strategic Differentiation: The Physics-First Moat
Schrödinger's core competitive advantage lies in its physics-based computational engine, which simulates atomic interactions with high fidelity to predict drug binding and molecular properties. This is significant because machine learning models are only as powerful as their training data, and experimental data alone is insufficient for robust AI training in drug discovery. The company's 35-year investment in physics simulations provides the "ground truth" that AI models require to navigate the vast universe of potential molecules with precision.
This technological differentiation translates directly to economic benefits. The platform enables customers to reduce preclinical failure rates and accelerate discovery timelines by months, creating quantifiable ROI that supports premium pricing. Top 20 pharma customers increased their annual contract value by 15% in 2025, while the average ACV per commercial customer spending over $1 million grew 16% to $3.9 million. These expanding relationships demonstrate that as customers scale their usage, the platform's value compounds, creating natural net dollar retention that reached 100% in 2025 despite macroeconomic pressures.
The company's R&D investments are targeting high-return opportunities. The predictive toxicology initiative, funded by the Bill & Melinda Gates Foundation and launching commercially in 2026, addresses a critical gap in preclinical testing. This initiative is timely because the FDA has explicitly stated its goal to reduce animal testing, creating a regulatory tailwind for computational alternatives. Early beta feedback has exceeded expectations, suggesting the solution can tap into new budgets from toxicology groups that are not current customers, expanding the addressable market beyond traditional computational chemistry users.
Financial Performance & Segment Dynamics: Evidence of Strategic Execution
Schrödinger's 2025 financial results provide clear evidence that the strategic pivot is working. Total revenue grew 23% to $255.9 million, driven by an 11% increase in software revenue and a 107% surge in drug discovery revenue. The net loss narrowed dramatically from $187.1 million in 2024 to $103.3 million in 2025, while operating cash flow turned positive at $13.9 million, a significant improvement from cash burn in prior periods.
The software segment's gross margin declined from 80% to 74% in 2025, but this reflects a deliberate strategic choice rather than competitive pressure. The margin compression stems from higher costs associated with Gates Foundation contribution revenue for the predictive toxicology project. Management expects gross margins to return to the high 70s by 2028 as this project completes, indicating the current headwind is temporary and tied directly to a future growth driver.
Drug discovery revenue volatility is a feature of the business model. The 107% growth in 2025 followed a 53% decline in 2024, demonstrating the lumpiness of milestone achievements. However, the underlying asset quality is improving: 16 collaborative programs are now eligible for future royalties, up from 13 in 2024, and the company has generated approximately $650 million in cash, upfronts, and milestones to date. This shows Schrödinger can monetize its platform through partnerships without bearing the full cost and risk of independent clinical development.
The May 2025 restructuring, which reduced headcount by 7% and will save $30 million annually, combined with the decision to end independent clinical development, creates approximately $70 million in total savings. This demonstrates management's discipline in allocating capital to the highest-return opportunities. Rather than dilute focus and capital on expensive Phase 2/3 trials, the company will partner its proprietary programs, preserving upside while eliminating the primary driver of cash burn.
Outlook, Management Guidance, and Execution Risk
Management's guidance for 2026 reveals a company in transition. Software ACV is expected to grow 10-15% to $218-228 million, while drug discovery revenue is projected at $55-65 million. The shift to ACV guidance provides clearer visibility into underlying business performance during the hosted transition, where revenue recognition timing obscures growth. Each 1% increase in hosted revenue percentage reduces current-year revenue by $2-3 million but does not impact total ACV or cash flows, making ACV the more relevant metric for investors.
The hosted transition represents a calculated near-term sacrifice for long-term gain. Management aims for 75% of software revenue to be hosted by 2028, driven by customer preference for faster deployment and enhanced support. This shift transforms the revenue model from lumpy upfront recognition to predictable ratable streams, improving valuation multiples and reducing earnings volatility. The mathematical consequence is that 2026 revenue will be lower than 2025, but the quality and predictability of that revenue will be substantially higher.
The path to positive adjusted EBITDA by 2028 depends on three key assumptions: 10-15% annual software ACV growth, approximately $50 million in annual drug discovery revenue, and continued operating expense discipline. This guidance appears credible given the $70 million in cost savings already identified and the strong balance sheet that requires no external capital. The company's cash position of $402 million provides a runway of at least 24 months, eliminating near-term financing risk.
Execution risk centers on the hosted transition and biotech sector recovery. Management acknowledged that pharma scale-up conversations have been delayed longer than anticipated, and biotech sector challenges have persisted beyond expectations. This could pressure near-term ACV growth, though the 15% growth in top 20 pharma ACV suggests large customers remain committed. The Q1 2026 ACV guidance of $24-28 million, roughly flat with Q1 2025, reflects this conservatism but also the seasonality of a smaller quarter.
Risks and Asymmetries: What Could Break the Thesis
Customer concentration poses a material risk, with the top 10 clients representing approximately 50% of revenue. If a major pharma customer consolidates vendors or develops internal capabilities, it could impact 20-25% of topline and cash flow. This makes Schrödinger more vulnerable to procurement changes than diversified competitors like Certara (CERT). However, the 96% gross dollar retention rate and the view of software as "necessary to have" provide some mitigation.
The biotech sector's persistent weakness creates a headwind for growth. Management noted that they did not anticipate the continued challenges, including layoffs, company shutdowns, and financing difficulties. This matters because the small/emerging biotech segment is experiencing "level-pegging" where growth from some customers offsets declines from others, limiting overall expansion. A recovery to normalized levels is expected within three years, but further deterioration could delay the 10-15% growth target.
Competition from AI-native drug discovery companies like Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) could erode Schrödinger's market share, particularly among cost-sensitive biotech startups. These competitors offer more accessible entry points that could pressure pricing by 5-10% in high-growth areas. However, Schrödinger's physics-first approach provides a defensible moat, as machine learning alone cannot replicate the accuracy of physics-based simulations without the extensive training data that Schrödinger has accumulated over 35 years.
The hosted transition creates execution risk. While customers increasingly prefer hosted deployments, the shift requires operational changes and could temporarily increase customer acquisition costs. If the transition to 75% hosted revenue by 2028 is delayed, the path to positive EBITDA could be pushed out, compressing valuation multiples.
Competitive Context: Positioning Against Peers
Schrödinger's competitive positioning reveals both strengths and vulnerabilities. Against Simulations Plus (SLP), Schrödinger offers materially greater efficiency in de novo molecule design and binding affinity predictions, enabling broader applications in early-stage drug design and materials science. While SLP grew 13% in 2025 with $79 million in revenue, Schrödinger's 23% growth and $256 million revenue demonstrate superior market capture in high-value segments. However, SLP's niche focus on PK/PD modeling provides lower upfront barriers for smaller customers, potentially limiting Schrödinger's penetration of the cost-sensitive biotech segment.
Versus Certara, Schrödinger leads in technological performance for complex simulations but lags in regulatory tool integration. Certara's 9% growth to $419 million revenue reflects its larger scale and services diversification, but Schrödinger's 81% software gross margins exceed Certara's blended ~70% margins. This positions Schrödinger for higher profitability at scale, though Certara's regulatory expertise provides steadier revenue from submissions and compliance work.
Compared to Evotec (EVO), Schrödinger's 23% growth and 81% software margins far exceed Evotec's -5% revenue trend and 13.6% gross margins. Evotec's service-heavy model faces disruption from faster AI pipelines, while Schrödinger's scalable software approach offers lower-cost validation. However, Evotec's broader biotech ecosystem and end-to-end service scale provide advantages in integrated discovery that Schrödinger lacks.
The key differentiator is Schrödinger's hybrid model. While pure software players like Simulations Plus and Certara lack proprietary validation, and service providers like Evotec lack scalable technology, Schrödinger combines both. This creates a unique value proposition where real-world drug discovery success validates the software platform, driving 16% growth in average ACV for large customers and supporting premium pricing.
Valuation Context: Mispriced Inflection Point
At $11.08 per share, Schrödinger trades at a market capitalization of $818 million and enterprise value of $532 million, representing 3.2x price-to-sales and 2.08x enterprise-to-revenue. This is significant because it places the stock at a discount to peers despite superior growth. Simulations Plus trades at 2.92x sales but with 13% growth versus Schrödinger's 23%, while Certara trades at 2.19x sales with 9% growth. The valuation gap suggests the market is pricing Schrödinger as a lower-quality asset despite its accelerating growth and improving margins.
The balance sheet strength provides a clear differentiation. With $402 million in cash and no debt, Schrödinger has a net cash position representing 49% of its market cap. This provides over two years of runway at current burn rates and eliminates financing risk, a significant advantage over competitors with higher leverage. The current ratio of 2.75 and quick ratio of 2.64 demonstrate strong liquidity, while the debt-to-equity ratio of 0.30 is conservative compared to Evotec's 0.61.
For an unprofitable company transitioning to profitability, revenue multiples and cash position are more relevant than earnings-based metrics. Schrödinger's price-to-operating cash flow of 58.9x reflects the recent turn to positive cash generation, while the negative operating margin of -19.7% is expected to improve as the $70 million in cost savings materializes. The path to positive adjusted EBITDA by 2028, supported by 10-15% software ACV growth and $50 million in annual drug discovery revenue, provides a clear catalyst for multiple expansion.
The stock's beta of 1.65 indicates higher volatility than the market, which is a factor for risk-adjusted returns but also creates opportunity for investors who recognize the inflection. Management's comment that the stock price "does not reflect our intrinsic value" while choosing to invest cash in growth rather than buybacks suggests they see significant upside potential from current levels.
Conclusion: The Convergence of Discipline and Differentiation
Schrödinger stands at a critical inflection where strategic discipline meets technological differentiation. The decision to end independent clinical development, while preserving partnership upside, eliminates the primary driver of cash burn and focuses resources on the higher-margin software business. This shift transforms Schrödinger from a capital-intensive biotech into a capital-efficient platform company, a change the market has not yet fully recognized in the valuation.
The physics-based computational platform provides a durable moat that becomes more valuable as AI adoption accelerates. Unlike competitors relying solely on machine learning, Schrödinger's 35-year accumulation of simulation data creates a barrier that cannot be quickly replicated. This positions the company to capture a disproportionate share of the growing computational drug discovery market while maintaining pricing power evidenced by 16% growth in large customer ACV.
The investment thesis hinges on execution of the hosted transition and successful partnering of the Phase 1 assets. If management delivers on its 2028 profitability target while maintaining 10-15% software growth, the current valuation of 3.2x sales will likely prove conservative. The key variables to monitor are ACV growth in Q4 2026, progress on SGR-1505 and SGR-3515 partnerships, and the pace of predictive toxicology adoption. Success on these fronts would validate the strategic pivot and drive meaningful re-rating, while execution missteps could delay the profitability timeline and compress multiples further.
